,Test Bank Pharmacotherapeutics for Advanced Practice Nurse Prescribers 6e Teri Moser
hh hh hh hh hh hh hh hh hh hh
Woo
hh
Woo 1
Pharmacotherapeutics hhfor hh APN hh Prescribers, hh 6e Ch01
Chapter 1. The Role of the Advanced Practice Nurse as Prescriber
hh hh hh hh hh hh hh hh hh hh
MULTIPLE hhCHOICE
1. Nurse hhpractitioner hhprescriptive hhauthority hhis hhregulated hhby:
A. The hhNational hhCouncil hhof hhState hhBoards hhof hhNursing
B. The hhU.S. hhDrug hhEnforcement hhAdministration
C. The hhState hhBoard hhof hhNursing hhfor hheach hhstate
D. The hhState hhBoard hhof hhPharmacy
ANS: h h C PTS: h h h h 1
2. The hhbenefits hhto hhthe hhpatient hhof hhhaving hhan hhadvanced hhpractice hhregistered hhnurse hh(APRN)
prescriber hhinclude:
hh
A. Nurses hhknow hhmore hhabout hhpharmacology hhthan hhother hhprescribers hhbecause hhthey
hhtake hhit hhboth hhin hhtheir hhbasic hhnursing hhprogram hhand hhin hhtheir hhAPRN hhprogram.
B. Nurses hhcare hhfor hhthe hhpatient hhfrom hha hhholistic hhapproach hhand hhinclude hhthe
hhpatient hhin hhdecision-making hhregarding hhtheir hhcare.
C. APRNs hhare hhless hhlikely hhto hhprescribe hhnarcotics hhand hhother hhcontrolled hhsubstances.
D. APRNs hhare hhable hhto hhprescribe hhindependently hhin hhall hhstates, hhwhereas hha
hhphysician’s hhassistant hhneeds hhto hhhave hha hhphysician hhsupervising hhtheir
hhpractice.
ANS: h h B PTS: h h h h 1
3. Clinical hhjudgment hhin hhprescribing hhincludes:
A. Factoring hhin hhthe hhcost hhto hhthe hhpatient hhof hhthe hhmedication hhprescribed
B. Always hhprescribing hhthe hhnewest hhmedication hhavailable hhfor hhthe hhdisease hhprocess
C. Handing hhout hhdrug hhsamples hhto hhpoor hhpatients
D. Prescribing hhall hhgeneric hhmedications hhto hhcut hhcosts
ANS: h h A PTS: h h h h 1
4. The hhprocess hhfor hhchoosing hhan hheffective hhdrug hhfor hha hhdisorder hhincludes:
A. Asking hhthe hhpatient hhwhat hhdrug hhthey hhthink hhwould hhwork hhbest hhfor hhthem
B. Consulting hhnationally hhrecognized hhguidelines hhfor hhdisease hhmanagement
C. Prescribing hhmedications hhthat hhare hhavailable hhas hhsamples hhbefore hhwriting hha hhprescription
D. Following hhU.S. hhDrug hhEnforcement hhAdministration hhguidelines hhfor hhprescribing
ANS: h h B PTS: h h h h 1
5. Nonintentional hhnonadherence hhof hhdrug hhtherapy hhmay hhoccur hhdue hhto:
A. Belief hhthat hhmedication hhdoes hhnot hhwork
B. Adverse hhdrug hhreactions
C. Chronic hhconditions hhthat hhrequire hhdaily hhtherapy
D. Forgetfulness hhor hhdistraction
ANS: h h D PTS: h h h h 1
, Woo 1
Pharmacotherapeutics for APN Prescribers, 6e Ch02
Chapter 2. Review of Basic Principles of Pharmacology
hh hh hh hh hh hh hh
MULTIPLE hhCHOICE
1. A hhpatient’s hhnutritional hhintake hhand hhlaboratory hhresults hhreflect hhhypoalbuminemia. hhThis hhis
critical hhto hhprescribing hhbecause:
hh
A. Distribution hhof hhdrugs hhto hhtarget hhtissue hhmay hhbe hhaffected.
B. The hhsolubility hhof hhthe hhdrug hhwill hhnot hhmatch hhthe hhsite hhof hhabsorption.
C. There hhwill hhbe hhless hhfree hhdrug hhavailable hhto hhgenerate hhan hheffect.
D. Drugs hhbound hhto hhalbumin hhare hhreadily hhexcreted hhby hhthe hhkidneys.
ANS: h h A PTS: h h h h 1
2. Drugs hhthat hhhave hha hhsignificant hhfirst-pass hheffect:
A. Must hhbe hhgiven hhby hhthe hhenteral hh(oral) hhroute hhonly
B. Bypass hhthe hhhepatic hhcirculation
C. Are hhrapidly hhmetabolized hhby hhthe hhliver hhand hhmay hhhave hhlittle, hhif hhany, hhdesired hhaction
D. Are hhconverted hhby hhthe hhliver hhto hhmore hhactive hhand hhfat-soluble hhforms
ANS: h h C PTS: h h h h 1
3. The hhroute hhof hhexcretion hhof hha hhvolatile hhdrug hhwill hhlikely hhbe hhthe:
A. Kidneys
B. Lungs
C. Bile hhand hhfeces
D. Skin
ANS: h h B PTS: h h h h 1
4. A hhmajor hhdisadvantage hhto hhIV hhadministration hhis hhthat:
A. First-pass hhmetabolism hhis hheliminated.
B. Needles hhand hhsterility hhare hhrequired.
C. Absorption hhof hhthe hhdrug hhcannot hhbe hhslowed hhafter hhadministration.
D. It hhis hhsignificantly hhmore hhexpensive hhthan hhother hhroutes.
ANS: h h C PTS: h h h h 1
5. The hhnurse hhpractitioner hh(NP) hhchooses hhto hhgive hhcephalexin hhevery hh8 hhhours hhbased hhon
knowledge hhof hhthe hhdrug’s:
hh
A. Propensity hhto hhgo hhto hhthe hhtarget hhreceptor
B. Biological hhhalf-life
C. Pharmacodynamics
D. Safety hhand hhside hheffects
ANS: h h B PTS: h h h h 1
6. Deferasirox hhis hha hhchelating hhagent hhused hhto hhtreat hhiron hhoverload hhby hhbinding hhiron hhto
render hhit hhbiologically hhinactive. hhThis hhis hhbest hhcharacterized hhas hha(n):
hh
, Woo 2
Pharmacotherapeutics for APN Prescribers, 6e Ch02
A. Nonreceptor hhmechanism
B. Partial hhagonist
C. Full hhagonist
D. Noncompetitive hhantagonist
ANS: h h A PTS: h h h h 1
7. The hhpoint hhin hhtime hhon hhthe hhdrug hhconcentration hhcurve hhthat hhindicates hhthe hhfirst hhsign hhof hha
therapeutic hheffect hhis hhthe:
hh
A. Minimum hhadverse hheffect hhlevel
B. Peak hhof hhaction
C. Onset hhof hhaction
D. Therapeutic hhrange
ANS: h h C PTS: h h h h 1
8. Phenytoin hhrequires hhthat hha hhtrough hhlevel hhbe hhdrawn. hhPeak hhand hhtrough hhlevels hhare hhdone:
A. When hhthe hhdrug hhhas hha hhwide hhtherapeutic hhrange
B. When hhthe hhdrug hhwill hhbe hhadministered hhfor hha hhshort hhtime hhonly
C. When hhthere hhis hha hhhigh hhcorrelation hhbetween hhthe hhdose hhand hhsaturation hhof hhreceptor hhsites
D. To hhdetermine hhif hha hhdrug hhis hhin hhthe hhtherapeutic hhrange
ANS: h h D PTS: h h h h 1
9. A hhlaboratory hhresult hhindicates hhthat hhthe hhpeak hhlevel hhfor hha hhdrug hhis hhabove hhthe
minimum hhtoxic hhconcentration. hhThis hhmeans hhthat hhthe:
hh
A. Concentration hhwill hhproduce hhtherapeutic hheffects.
B. Concentration hhwill hhproduce hhan hhadverse hhresponse.
C. Time hhbetween hhdoses hhmust hhbe hhshortened.
D. Duration hhof hhaction hhof hhthe hhdrug hhis hhtoo hhlong.
ANS: h h B PTS: h h h h 1
10. Drugs hhthat hhare hhreceptor hhagonists hhmay hhdemonstrate hhwhat hhproperty?
A. Irreversible hhbinding hhto hhthe hhdrug hhreceptor hhsite
B. Up-regulation hhwith hhchronic hhuse
C. Desensitization hhor hhdown-regulation hhwith hhcontinuous hhuse
D. Inverse hhrelationship hhbetween hhdrug hhconcentration hhand hhdrug hhaction
ANS: h h C PTS: h h h h 1
11. Drugs hhthat hhare hhreceptor hhantagonists, hhsuch hhas hhbeta hhblockers, hhmay hhcause:
A. Down-regulation hhof hhthe hhdrug hhreceptor
B. An hhexaggerated hhresponse hhif hhabruptly hhdiscontinued
C. Partial hhblockade hhof hhthe hheffects hhof hhagonist hhdrugs
D. An hhexaggerated hhresponse hhto hhcompetitive hhdrug hhagonists
ANS: h h B PTS: h h h h 1
hh hh hh hh hh hh hh hh hh hh
Woo
hh
Woo 1
Pharmacotherapeutics hhfor hh APN hh Prescribers, hh 6e Ch01
Chapter 1. The Role of the Advanced Practice Nurse as Prescriber
hh hh hh hh hh hh hh hh hh hh
MULTIPLE hhCHOICE
1. Nurse hhpractitioner hhprescriptive hhauthority hhis hhregulated hhby:
A. The hhNational hhCouncil hhof hhState hhBoards hhof hhNursing
B. The hhU.S. hhDrug hhEnforcement hhAdministration
C. The hhState hhBoard hhof hhNursing hhfor hheach hhstate
D. The hhState hhBoard hhof hhPharmacy
ANS: h h C PTS: h h h h 1
2. The hhbenefits hhto hhthe hhpatient hhof hhhaving hhan hhadvanced hhpractice hhregistered hhnurse hh(APRN)
prescriber hhinclude:
hh
A. Nurses hhknow hhmore hhabout hhpharmacology hhthan hhother hhprescribers hhbecause hhthey
hhtake hhit hhboth hhin hhtheir hhbasic hhnursing hhprogram hhand hhin hhtheir hhAPRN hhprogram.
B. Nurses hhcare hhfor hhthe hhpatient hhfrom hha hhholistic hhapproach hhand hhinclude hhthe
hhpatient hhin hhdecision-making hhregarding hhtheir hhcare.
C. APRNs hhare hhless hhlikely hhto hhprescribe hhnarcotics hhand hhother hhcontrolled hhsubstances.
D. APRNs hhare hhable hhto hhprescribe hhindependently hhin hhall hhstates, hhwhereas hha
hhphysician’s hhassistant hhneeds hhto hhhave hha hhphysician hhsupervising hhtheir
hhpractice.
ANS: h h B PTS: h h h h 1
3. Clinical hhjudgment hhin hhprescribing hhincludes:
A. Factoring hhin hhthe hhcost hhto hhthe hhpatient hhof hhthe hhmedication hhprescribed
B. Always hhprescribing hhthe hhnewest hhmedication hhavailable hhfor hhthe hhdisease hhprocess
C. Handing hhout hhdrug hhsamples hhto hhpoor hhpatients
D. Prescribing hhall hhgeneric hhmedications hhto hhcut hhcosts
ANS: h h A PTS: h h h h 1
4. The hhprocess hhfor hhchoosing hhan hheffective hhdrug hhfor hha hhdisorder hhincludes:
A. Asking hhthe hhpatient hhwhat hhdrug hhthey hhthink hhwould hhwork hhbest hhfor hhthem
B. Consulting hhnationally hhrecognized hhguidelines hhfor hhdisease hhmanagement
C. Prescribing hhmedications hhthat hhare hhavailable hhas hhsamples hhbefore hhwriting hha hhprescription
D. Following hhU.S. hhDrug hhEnforcement hhAdministration hhguidelines hhfor hhprescribing
ANS: h h B PTS: h h h h 1
5. Nonintentional hhnonadherence hhof hhdrug hhtherapy hhmay hhoccur hhdue hhto:
A. Belief hhthat hhmedication hhdoes hhnot hhwork
B. Adverse hhdrug hhreactions
C. Chronic hhconditions hhthat hhrequire hhdaily hhtherapy
D. Forgetfulness hhor hhdistraction
ANS: h h D PTS: h h h h 1
, Woo 1
Pharmacotherapeutics for APN Prescribers, 6e Ch02
Chapter 2. Review of Basic Principles of Pharmacology
hh hh hh hh hh hh hh
MULTIPLE hhCHOICE
1. A hhpatient’s hhnutritional hhintake hhand hhlaboratory hhresults hhreflect hhhypoalbuminemia. hhThis hhis
critical hhto hhprescribing hhbecause:
hh
A. Distribution hhof hhdrugs hhto hhtarget hhtissue hhmay hhbe hhaffected.
B. The hhsolubility hhof hhthe hhdrug hhwill hhnot hhmatch hhthe hhsite hhof hhabsorption.
C. There hhwill hhbe hhless hhfree hhdrug hhavailable hhto hhgenerate hhan hheffect.
D. Drugs hhbound hhto hhalbumin hhare hhreadily hhexcreted hhby hhthe hhkidneys.
ANS: h h A PTS: h h h h 1
2. Drugs hhthat hhhave hha hhsignificant hhfirst-pass hheffect:
A. Must hhbe hhgiven hhby hhthe hhenteral hh(oral) hhroute hhonly
B. Bypass hhthe hhhepatic hhcirculation
C. Are hhrapidly hhmetabolized hhby hhthe hhliver hhand hhmay hhhave hhlittle, hhif hhany, hhdesired hhaction
D. Are hhconverted hhby hhthe hhliver hhto hhmore hhactive hhand hhfat-soluble hhforms
ANS: h h C PTS: h h h h 1
3. The hhroute hhof hhexcretion hhof hha hhvolatile hhdrug hhwill hhlikely hhbe hhthe:
A. Kidneys
B. Lungs
C. Bile hhand hhfeces
D. Skin
ANS: h h B PTS: h h h h 1
4. A hhmajor hhdisadvantage hhto hhIV hhadministration hhis hhthat:
A. First-pass hhmetabolism hhis hheliminated.
B. Needles hhand hhsterility hhare hhrequired.
C. Absorption hhof hhthe hhdrug hhcannot hhbe hhslowed hhafter hhadministration.
D. It hhis hhsignificantly hhmore hhexpensive hhthan hhother hhroutes.
ANS: h h C PTS: h h h h 1
5. The hhnurse hhpractitioner hh(NP) hhchooses hhto hhgive hhcephalexin hhevery hh8 hhhours hhbased hhon
knowledge hhof hhthe hhdrug’s:
hh
A. Propensity hhto hhgo hhto hhthe hhtarget hhreceptor
B. Biological hhhalf-life
C. Pharmacodynamics
D. Safety hhand hhside hheffects
ANS: h h B PTS: h h h h 1
6. Deferasirox hhis hha hhchelating hhagent hhused hhto hhtreat hhiron hhoverload hhby hhbinding hhiron hhto
render hhit hhbiologically hhinactive. hhThis hhis hhbest hhcharacterized hhas hha(n):
hh
, Woo 2
Pharmacotherapeutics for APN Prescribers, 6e Ch02
A. Nonreceptor hhmechanism
B. Partial hhagonist
C. Full hhagonist
D. Noncompetitive hhantagonist
ANS: h h A PTS: h h h h 1
7. The hhpoint hhin hhtime hhon hhthe hhdrug hhconcentration hhcurve hhthat hhindicates hhthe hhfirst hhsign hhof hha
therapeutic hheffect hhis hhthe:
hh
A. Minimum hhadverse hheffect hhlevel
B. Peak hhof hhaction
C. Onset hhof hhaction
D. Therapeutic hhrange
ANS: h h C PTS: h h h h 1
8. Phenytoin hhrequires hhthat hha hhtrough hhlevel hhbe hhdrawn. hhPeak hhand hhtrough hhlevels hhare hhdone:
A. When hhthe hhdrug hhhas hha hhwide hhtherapeutic hhrange
B. When hhthe hhdrug hhwill hhbe hhadministered hhfor hha hhshort hhtime hhonly
C. When hhthere hhis hha hhhigh hhcorrelation hhbetween hhthe hhdose hhand hhsaturation hhof hhreceptor hhsites
D. To hhdetermine hhif hha hhdrug hhis hhin hhthe hhtherapeutic hhrange
ANS: h h D PTS: h h h h 1
9. A hhlaboratory hhresult hhindicates hhthat hhthe hhpeak hhlevel hhfor hha hhdrug hhis hhabove hhthe
minimum hhtoxic hhconcentration. hhThis hhmeans hhthat hhthe:
hh
A. Concentration hhwill hhproduce hhtherapeutic hheffects.
B. Concentration hhwill hhproduce hhan hhadverse hhresponse.
C. Time hhbetween hhdoses hhmust hhbe hhshortened.
D. Duration hhof hhaction hhof hhthe hhdrug hhis hhtoo hhlong.
ANS: h h B PTS: h h h h 1
10. Drugs hhthat hhare hhreceptor hhagonists hhmay hhdemonstrate hhwhat hhproperty?
A. Irreversible hhbinding hhto hhthe hhdrug hhreceptor hhsite
B. Up-regulation hhwith hhchronic hhuse
C. Desensitization hhor hhdown-regulation hhwith hhcontinuous hhuse
D. Inverse hhrelationship hhbetween hhdrug hhconcentration hhand hhdrug hhaction
ANS: h h C PTS: h h h h 1
11. Drugs hhthat hhare hhreceptor hhantagonists, hhsuch hhas hhbeta hhblockers, hhmay hhcause:
A. Down-regulation hhof hhthe hhdrug hhreceptor
B. An hhexaggerated hhresponse hhif hhabruptly hhdiscontinued
C. Partial hhblockade hhof hhthe hheffects hhof hhagonist hhdrugs
D. An hhexaggerated hhresponse hhto hhcompetitive hhdrug hhagonists
ANS: h h B PTS: h h h h 1
